Viscient Bio

Replacing Animal Testing In Drug Trials

About this Event

Due to the inaccuracy of animal models that are widely used in preclinical drug validation, only 8% of drugs that enter Phase 1 clinical trials make it to market. Building drugs with a better method can lead to much higher chances of success and boost the expected return from a biotech investment.

Viscient Biosciences has built a proprietary drug discovery and development platform that improves the odds of success by using donor cells that have the actual disease being studied built into 3D tissues made with bioprinting and other methods to recreate the disease in a dish. This allows them to test drugs on human tissues with the proven disease, a more realistic environment for both efficacy and toxicity, significantly increasing the likelihood of later success. The exact success rates are not yet known, but Viscient’s internal data shows >95% accuracy at predicting drug success or failure in their disease area, which suggests a very high chance of success for the drugs they have developed using these models.

Viscient is currently using their platform in two development programs focused on liver disease with a total addressable market of $50B. Ultimately, the platform can be applied to all soft-tissue diseases. which will allow the company to create product after product against a wide range of indications ranging from rare disease to cancers either by discovering new drugs or licensing and repurposing existing medicines in novel ways.

Video On Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.